IO Biotech Inc IOBT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IOBT is a good fit for your portfolio.
News
-
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
-
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
-
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
-
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
-
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
-
IO Biotech to Present at 44th Annual Cowen Health Care Conference
Trading Information
- Previous Close Price
- $1.48
- Day Range
- $1.41–1.55
- 52-Week Range
- $0.82–2.64
- Bid/Ask
- $1.37 / $1.52
- Market Cap
- $94.87 Mil
- Volume/Avg
- 78,243 / 147,439
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 68
- Website
- https://www.iobiotech.com
Comparables
Valuation
Metric
|
IOBT
|
CGEM
|
CELC
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.73 | 1.48 | 3.20 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
IOBT
|
CGEM
|
CELC
|
---|---|---|---|
Quick Ratio | 9.18 | 16.60 | 12.78 |
Current Ratio | 9.37 | 17.07 | 13.43 |
Interest Coverage | — | — | −12.43 |
Quick Ratio
IOBT
CGEM
CELC
Profitability
Metric
|
IOBT
|
CGEM
|
CELC
|
---|---|---|---|
Return on Assets (Normalized) | −54.82% | −24.60% | −35.57% |
Return on Equity (Normalized) | −60.74% | −25.95% | −49.08% |
Return on Invested Capital (Normalized) | −62.98% | −29.67% | −39.21% |
Return on Assets
IOBT
CGEM
CELC
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jnpfcfvll | Vxhh | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Mvmqryzb | Byvkwj | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pbkcnsr | Vxppmvk | $98.8 Bil | |
MRNA
| Moderna Inc | Kdtdxgkn | Npkv | $38.8 Bil | |
ARGX
| argenx SE ADR | Zwqrrvn | Yzwp | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Kkmfbxm | Wvj | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fwnhcqxp | Gfhlgk | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vgdrmdpzh | Jbpmkf | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mqsjmtmmrm | Mtqrx | $12.4 Bil | |
INCY
| Incyte Corp | Fjwblpjt | Wxbydz | $11.9 Bil |